All CRT patients followed at our institution were prospectively enrolled in a research database. Patients were selected from this database for inclusion in this study if they were implanted with a CRT-D for approved indications during the enrollment period between 2004 and 2010 (New York Heart Association [NYHA] class III/IV symptoms; LVEF <35%; QRS duration >120 ms) and followed at our clinic. Patients with ischemic and nonischemic HF were enrolled.
C ardiac resynchronization therapy (CRT) is an important device for the treatment of patients with congestive heart failure (HF) with systolic dysfunction and dyssynchrony, as evidenced by a prolonged QRS interval on a surface ECG. Many randomized trials have demonstrated that CRT is associated with a decrease in HF symptoms, HF hospitalizations, and all-cause mortality. [1] [2] [3] [4] [5] CRT has, therefore, become an important tool in the treatment of HF.
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The relationship between CRT and the incidence of ventricular arrhythmias (VAs) remains controversial. Initial reports regarding CRT therapy and its effect on VAs were conflicting, with some suggesting an increased risk of VAs and ventricular tachycardia (VT) storm. [6] [7] [8] More recent analyses have suggested that CRT patients with on-treatment reverse remodeling, as evidenced by increases in the left ventricular ejection fraction (LVEF) or decreases in left ventricular end-diastolic volume, have a decreased burden of device-treated VAs. [9] [10] [11] Although CRT is associated with a decreased arrhythmia burden in echocardiographic responders, the population as a whole remains at elevated risk for incident VT and ventricular fibrillation (VF), and little is known about which baseline patient characteristics are able to identify patients at increased and decreased risk for incident arrhythmic events, information that might be useful when assessing the need for antiarrhythmic drugs or catheter ablation and the likelihood of receiving device therapy. In this study, we performed an analysis of a cohort of patients with CRT with defibrillator (CRT-D) to identify preimplant characteristics that may be useful in the risk stratification for incident VAs. data were available for 87% of patients. Left ventricular diameter measurements were made using the parasternal long-axis view, and LVEF measurement was typically obtained using the Teich method. Left ventricular mass index (LVMI) was defined as (1.04 [intraventricular septum+left ventricular end-diastolic diameter [LVEDD]+posterior wall] 3 -LVEDD 3 ]-14 g)/body surface area. Follow-up echocardiograms were obtained ≈6 months after device implantation. Echocardiographic response was defined as either ≥5% absolute increase in LVEF or 10% decrease in left ventricular end-systolic diameter (LVESD). Continuous variables were analyzed as categorical variables using previously accepted partitions or an upper quartile cutoff for initial investigations. Multiple partition values were tested for candidate variables.
Device Implantation and Programming
CRT-D implantation, programming, and device selection were at the discretion of the treating electrophysiologist. Left ventricular lead implantation was preferentially endovascular, although epicardial implantation occasionally occurred (5.9%) after failure of an endovascular attempt. Devices were usually programmed to initially treat VT with antitachycardia pacing (ATP), followed by high-voltage shocks if ATP was unsuccessful. VF was treated with high-voltage shocks. Detection and therapy zones were not standardized and were determined on an individual basis, although generally therapy zones began at 160 to 190 beats per minute. Recurrent episodes of symptomatic slow VT prompted lowering of therapy zones in certain instances.
End Points
The primary end point of the study was first incident sustained VA receiving appropriate device therapy after implantation of CRT-D. Arrhythmias were classified as VT, VF, electrical storm (appropriate therapy for 3 VAs within <24 hours), or pair of arrhythmias (appropriate therapy for 2 VAs within <24 hours). Appropriate therapy was defined as device therapy for a VA delivered according to prespecified parameters and as verified by electrophysiologist review of device electrograms. A single episode of VA requiring multiple therapies (ie, multiple rounds of ATP, multiple rounds of shock, or ATP followed by shock[s] for termination) was classified as a single event. This end point excluded nonsustained VT and inappropriate therapies for atrial arrhythmias or other factors (ie, lead fracture, oversensing) and does not imply that first therapy attempt was successful.
Incident hospitalization for HF, death, and a composite end point of death, left ventricular assist device (LVAD) implantation, or heart transplantation were also examined to assess outcomes among patients with and without appropriate therapy and with and without evidence of echocardiographic reverse remodeling.
Statistical Analysis
All statistical analyses were performed using SPSS, version 20.0 (SPSS Inc, Chicago, IL) or SAS, version 9.3 (SAS Institute Inc, Cary, NC). All continuous variables were found to be normally distributed based on inspection of histograms and comparison of each variable's mean, median, and 5% trimmed mean. Baseline characteristics of patients are presented as mean±SD for continuous variables and as proportions for categorical variables. Differences among proportions were assessed using Pearson χ 2 or Fisher exact test, where appropriate, and differences in mean values were compared with Student t tests. Kaplan-Meier curves were constructed to compare event rates in different subgroups and were formally assessed using log-rank testing. Univariate and multivariate analyses were performed using Cox proportional hazards models; forward stepwise selection was used for multivariate analyses. Significant univariate predictors at the P<0.10 level were tested for inclusion in multivariate models, unless otherwise specified. For all tests, P<0.05 was required for statistical significance. For the second multivariate analysis assessing predictors of arrhythmia in patients with LVESD ≤61 mm, all univariate predictors from the primary analysis were considered, along with variables that differed among patients when divided by the 61-mm LVESD partition.
Results

Baseline Characteristics and Incident Device-Treated Arrhythmia
Two hundred sixty-nine patients (mean age, 68.2±12.5 years; average LVEF, 23.9±6.8%) were followed for 553±464 days after CRT-D implantation. Of these patients, 21% were women, 54% had ischemic cardiomyopathy, 8% had NYHA class IV symptom status, and 18% had a history of sustained VA. Subjects had a prolonged QRS (mean QRS, 161±29 ms, with QRS >150 ms in 60% of individuals) and dilated left ventricle (mean LVEDD of 62.6±8.7 mm and LVESD of 54.6±8.9 mm). Nearly 3 quarters (73%) of patients had hypertension, 40% had diabetes mellitus, and 62% had coronary artery disease. The majority of patients were taking β-blockers (91%), angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (83%), and diuretics (85%). Three of the 85 patients (4%) with chronic atrial fibrillation underwent atrioventricular junctional ablation at the time of implantation. The most common antiarrhythmic drug was amiodarone (19% of patients.) Additional baseline characteristics are detailed in Table 1 .
Of the 269 patients who were followed, 60 (22%) had appropriate therapy for VT or VF (mean rate, 202±39 beats per minute [range, 125-333 beats per minute]; 21 episodes <188 beats per minute, 29 episodes between 188 and 250 beats per minute, 9 episodes >250 beats per minute, 1 episode with missing rate data) during follow-up. Of these first therapies, 44 were for VT, 6 were for VF, 6 were for electrical storms, and 4 were for a pair of VAs within <24 hours. Of these patients, 41% (n=25) had at least 1 additional appropriate device discharge, and during follow-up there were a total of 121 arrhythmic events. Kaplan-Meier modeling predicts 1-, 2-, 3-, and 4-year incidences of appropriate therapy to be 18%, 25%, 33%, and 36%, respectively, in the overall cohort ( Figure 1 ).
Baseline characteristics of patients with and without appropriate therapy during follow-up are detailed in Table 2 . Patients with appropriate device therapy were more likely to have a history of sustained VA (30% versus 15%; P=0.009), previous percutaneous coronary intervention (PCI) (38% versus 24%; P=0.033), and be off β-blocker therapy (20% versus 6%; P=0.001.) They were also more likely to have a lower LVEF (22.0±6.4% versus 24.4±6.9%; P=0.022) and dilated left ventricle (LVESD 58.2±9.7 mm versus 53.6± 8.4 mm; P=0.001; LVEDD 66.0±9.9 mm versus 61.6±8.0 mm; P=0.001). Patients who did not require device therapy trended toward being more likely to be women (23% versus 12%; P=0.050) and NYHA class IV (10% versus 2%; P=0.053.) There were no differences between groups with regard to medical comorbidities, renal function, QRS duration, age, body mass index, atrial fibrillation, digoxin use, or whether CRT-D implant was performed as an upgrade from implantable cardioverter-defibrillator (ICD). Of note, patients with baseline echocardiograms (87% of population) were less likely to have undergone upgrade from a pacemaker to CRT-D (5% versus 19%; P=0.009) but were otherwise similar. August 2012
Predictors of Appropriate Device Therapy
All available baseline characteristics listed in Tables 1 and  2 were considered to be potential predictors of appropriate device therapy for the primary analysis. An upper quartile cutoff was initially used to evaluate LVESD, LVEDD, and LVMI. Significant univariate predictors of therapy include LVEF <20%, history of sustained VT or VF, absence of β-blocker therapy, LVESD >61 mm, LVEDD >68 mm, and LVMI >162 g/m 2 (Table 3) ; the partition values for LVESD, LVEDD, and LVMI represent the upper quartile values for the study population. Given that the time of study enrollment could impact risk of arrhythmia owing to changes in practice in device implantation and programming, as well as patient selection, we assess the relative hazard of late implantation compared with earlier implantation, and Cox modeling demonstrates a nonsignificant difference in risk of VA (hazard ratio [HR], 0.85; 95% CI, 0.49-1.49; P=0.58). Male sex and history of PCI demonstrated a nonsignificant trend toward increased risk of appropriate device therapy in the univariate analysis. LVESD, LVEDD, and LVMI were all highly correlated metrics, given their dependence on left ventricular dilation; when all 3 variables were included in a multivariate analysis with forward stepwise selection, LVESD was the only significant predictor and thus was used for all subsequent analyses. Kaplan-Meier analysis was performed to assess arrhythmia risk by quartile of LVESD; the curves representing the lower 3 quartiles of LVESD were overlapping, whereas the upper quartile remained divergent throughout follow-up, further supporting this partition ( Figure 2 ). Other LVESD partitions (60th, 80th, and 90th percentiles) were tested and found to be inferior to the upper quartile cut-off.
A multivariate model considering LVESD, absence of β-blocker therapy, history of sustained VA, gender, PCI, and LVEF <20% identified LVESD >61 mm and history of PCI as the only independent predictors of incident VA (HR, NYHA indicates New York Heart Association Symptom Class; BMI, body mass index; LV, left ventricular; ICD, implantable cardioverter-defibrillator; CABG, coronary artery bypass grafting; CAD, coronary artery disease; Cr, creatinine; CM, cardiomyopathy; PCI, percutaneous coronary intervention; VT, ventricular tachycardia; VF, ventricular fibrillation; MR, mitral regurgitation; IVS, intraventricular septum; AP, anteroposterior; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; PWT, posterior wall thickness; RVSP, right ventricular systolic pressure; ACE/ARB, angiotensin-converting enzyme/ angiotensin receptor blocker. 2.66; HR, 1.52-4.65; P=0.001) and (HR, 1.92; CI, 1.10-3.35; P=0.022), respectively ( Table 4 ). Three-year incidence of VA among those with a history of PCI (n=72) was 46% compared with 28% among those without a history of PCI (n=197; P=0.063). Although the predictive value associated with a history of PCI may underscore the importance of revascularization for the reduction of arrhythmias, the relationship may be somewhat confounded by the fact that those who underwent PCI may have been too ill to undergo more complete revascularization (eg, coronary artery bypass grafting) or underwent PCI as a salvage procedure after coronary artery bypass grafting. Given that the predictive value is likely related to confounding by indication, it was not used in subsequent models.
Three-year incidence of VA among those with LVESD >61 mm (n=63) was 51% compared with 26% among those with LVESD ≤61 mm (n=174; P=0.001) ( Figure 3A ). Of note, the rates of first treated VA did not differ based on more or less ventricular dilation (202 beats per minute versus 201 beats per minute, respectively; P=0.97). Table 5 describes differences in baseline characteristics between patients with and without LVESD >61 mm; none of these characteristics were univariate predictors of VAs. The rates of HF hospitalization, all-cause mortality, and LVAD, transplant, or death among patients with and without LVESD >61 mm are detailed in Figure 3B to 3D, respectively. LVESD >61 mm was associated with increased rates of HF hospitalization (P=0.006) and a trend toward increased rates of all-cause mortality and the composite end point.
Further risk stratification was pursued with a multivariate analysis of those with LVESD ≤61 mm (n=174) using significant univariate predictors from the primary analysis. Absence of β-blocker therapy (HR, 6.34; 95% CI, 2.28-17.65; P<0.001), LVEF <20% (HR, 4.22; 95% CI, 1.88-9.47; P<0.001), and history of sustained VA (HR, 2.97; 95% CI, 1.25-7.02; P=0.013) were significant multivariate predictors and improved the overall risk stratification (Table 4 ). There was a significant interaction between LVESD >61 mm and LVEF <20% (P=0.022) and LVESD >61 mm and absence of β-blocker therapy (P=0.013). In contrast, there was no significant interaction between LVESD >61 mm and history of VA (P=0.49).
Individuals without any of these risk factors (LVESD >61 mm, LVEF <20%, absence of β-blocker therapy, and a history of VA) demonstrated a 21% 3-year incidence of VA versus a 41% 3-year incidence among those with LVESD ≤61 mm and at least 1 additional risk factor (log rank, 16.4321; P<0.001). Figure 4 demonstrates that among those with LVESD ≤61 mm, an increasing number of risk factors is associated with a stepwise increase in risk of VA (overall, P<0.001); those with 0, 1, or 2+ risk factors demonstrated a 3-year VA incidence of 21%, 35%, and 75%, respectively.
Reverse Remodeling and Relationship to Outcomes
Reverse remodeling and its relationship to incident VA, HF hospitalization, and a combined end point of death, LVAD, or cardiac transplantation were examined in 154 patients with 6-month follow-up echocardiograms. Echocardiograms occurred 201±41 days after implantation. Compared with those with follow-up studies, the group without follow-up studies had more epicardial leads (11% versus 3%; P=0.039), ICD upgrades (46% versus 32%; P=0.033), paroxysmal atrial fibrillation (33% versus 21%; P=0.046), and lower body mass index (mean 27 kg/m 2 versus 28 kg/m 2 ; P=0.034). When assessed using proportional hazards modeling, lack of follow-up echocardiographic data was not a marker of increased mortality, HF hospitalization, or VA, and thus lack of follow-up studies was not likely related to early adverse outcomes that precluded follow-up.
Baseline and follow-up echocardiographic measurements of patients divided by LVESD are detailed in Table 6 . Although both groups of patients experienced reverse remodeling, those with an LVESD >61 mm had a more enlarged left ventricle, depressed LVEF, and more severe mitral regurgitation at both baseline and follow-up. Furthermore, those with baseline LVESD >61 mm demonstrated a lesser degree of reverse remodeling after CRT.
The relationship between composite echocardiographic response and outcomes is listed in Table 7 . Although response is associated with a decreased risk of VA (HR, 0.51; 95% CI, 0.27-0.96; P=0.037), it is no longer significant when included in a multivariate model with baseline LVESD >61 mm (HR, 0.62; 95% CI, 0.32-1.18; P=0. 15 ), suggesting that while echocardiographic response to CRT is important in assessing prognosis, response is a relative measure and must be interpreted in the context of the severity of the baseline underlying cardiomyopathy. Table 7 also details how response is associated with reduced risk of death, LVAD, or transplant, and a trend toward decreased risk of HF hospitalization and death. The prognostic significance of reverse remodeling in the prediction of other outcomes was also somewhat attenuated after adjustment for LVESD >61 mm: HF hospitalization (HR, 0.70; 95% CI, 0.40-1.23; P=0.21), death (HR, 0.57; 95% CI, 0.28-1.12; P=0.13), and death, LVAD, or transplant (HR, 0.49; 95% CI, 0.25-0.96; P=0.038).
We additionally analyzed whether the clinical impact of echocardiographic response varied according to baseline LVESD. Among patients with LVESD >61 mm and followup echocardiograms (n=39), echocardiographic evidence of response did not significantly predict decreased risk for arrhythmia (HR, 0.646; 95% CI, 0.260-1.607; P=0.35) as it did in the overall population, although the point estimate suggests a possible protective effect. However, this may be related to sample size as the subgroup of patients with LVESD ≤61 mm and follow-up echocardiograms (n=115) only demonstrated a trend toward decreased incidence of arrhythmias (HR, 0.590; 95% CI, 0.241-1.445; P=0.25).
Outcomes in Patients With Appropriate Device Therapy
We subsequently examined association between incident VA, modeled as a time-varying covariate, and risk of mortality, HF hospitalization, and a composite end point of death, LVAD implantation, or cardiac transplant. Events were stratified according to therapy type (ATP, shock, or any therapy) and timing of therapy relative to implant (<180 days, ≥180 days, or any time after implant), and the results are detailed in Table 8 . The results of multivariate adjustment with age, cardiomyopathy type, LVEF <20%, and sex are detailed in Table 9 . Shocks were associated with a substantially increased risk of HF hospitalization, mortality, and the composite end point. Any therapy (ATP or shock) and early therapies were also associated with increased risk for all 3 end points, although this relationship seemed to be largely driven by the impact of shocks. Given that early shock may be a marker of frequent arrhythmia, we attempted to separate the effect of recurrent arrhythmias from early shock by repeating a multivariate analysis, excluding patients with multiple VAs during follow-up; early shock remained a robust predictor of mortality (HR, 4.61; 95% CI, 1.94-10.94; P<0.001), and the point estimate and CIs remained unchanged even when adjusting for >1 shock delivered for the VA into the model. HF hospitalization was predicted by any shock, early shock, late shock, early electric therapy (ATP or shock), and any electric therapy (Table 9 ). In addition, there was no difference in the incidence of death, HF hospitalization, or death, LVAD, or transplant when patients with arrhythmias were divided based on the rate of their first arrhythmia (rate <180 beats per minute, 180-250 beats per minute, >250 beats per minute). 
Discussion
Predictors of Appropriate Device Therapy
In this study, we demonstrate that baseline LVESD is a powerful independent predictor of appropriate device therapy in patients undergoing CRT-D, outperforming the conventionally used LVEF in risk stratification. To our knowledge, this is the first time LVESD has been identified as a predictor of VA in a population of patients with HF undergoing CRT-D. We have further demonstrated that among patients with LVESD ≤61 mm, absence of β-blocker therapy, history of sustained VA, and LVEF <20% are useful for further risk stratification. Other studies [12] [13] [14] have identified preimplantation predictors of appropriate device therapy in a CRT population. Although these studies have demonstrated some variability in results, sex, 12 absence of β-blocker therapy, 12 absence of angiotensinconverting enzyme or angiotensin receptor blocker therapy, 12 NYHA class IV status, 12, 13 LVEF <20%, 14 and history of VA (either sustained 13 or nonsustained 14 ) were significant predictors of VA. There were important differences between these and our studies that should be noted. The COMPANION study 12 excluded patients with previous sustained VAs, and thus this metric cannot be studied in this cohort. There was less β-blocker utilization in the COMPANION 12 and Ventak CHF/Contak CD 13 analyses than would be expected in a contemporary cohort of HF patients (68% in the COMPANION cohort and 49% in the Ventak CHF/Contak CD cohort, compared with 91% in our study), potentially limiting the generalizability of these results to the current era. Furthermore, these previous reports 12, 13 were analyses of randomized trials that excluded patients with atrial fibrillation, a condition that is highly prevalent and problematic in contemporary CRT cohorts. Notably, the analysis by Soliman et al 14 includes only men with NYHA class III symptom status at the time of device implant. In contrast, our analysis includes men and women of both NYHA class III/IV on excellent medical therapy, with a variety of arrhythmic comorbidities (ie, sustained VAs, atrial fibrillation), comprising a real-world population.
Although much work has been done on VA risk stratification in patients with HF meeting criteria for ICD implantation, patients with CRT are different in many important ways, potentially limiting the extent to which results of ICD trials can be generalized to a CRT population. Patients with CRT are generally sicker than patients with an ICD based on the traditional implantation requirements for more advanced symptom status and conduction disease (as defined by prolonged QRS). Furthermore, biventricular pacing is a dynamic therapy that has the potential to alter several factors, including neurohormonal activation (ie norepinephrine), 15 wall tension, 11 oxygen consumption, 16 left ventricular mass, 17, 18 and left ventricular size, 17, 19 which may be important in the genesis of VAs. 20 In addition, biventricular pacing decreases conduction delays and pauses, which are important for macroreentrant and pause-dependent arrhythmias, respectively. 21
Clinical Implications
The metric LVESD is a simple, widely available, reproducible, and physiologically relevant tool for the risk stratification of VAs among patients with systolic dysfunction, which LVESD indicates left ventricular end-systolic diameter; NYHA, New York Heart Association Symptom Class; BMI, body mass index; LV, left ventricular; ICD, implantable cardioverter-defibrillator; CABG, coronary artery bypass grafting; CAD, coronary artery disease; Cr, creatinine; CM, cardiomyopathy; PCI, percutaneous coronary intervention; VT, ventricular tachycardia; VF, ventricular fibrillation; MR, mitral regurgitation; IVS, intraventricular septum; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; N/A, not applicable; RVSP, right ventricular systolic pressure; ACE/ARB, angiotensinconverting enzyme/angiotensin receptor blocker.
integrates elements of both ventricular size and function because its measurement occurs during systole, the time of maximal myocardial contraction. Ventricular dilation is proportional to wall stress, potentially explaining the relationship between dilated ventricles and risk for VAs. LVESD may be clinically useful for identifying patients with CRT at particularly high risk for incident VAs. Although the absence of β-blocker therapy, history of sustained VA, and LVEF <20% are all markers of increased risk among patients with less dilated ventricles (LVESD ≤61 mm), those without any of the 4 identified risk factors remain at substantial risk for incident VA (21% over 3 years) and thus should continue to be considered for defibrillator implantation at the time of CRT implantation.
Whether prophylactic defibrillators should be considered among patients with CRT receiving devices for newer indications is an interesting and relevant question as several trials are assessing or have suggested CRT efficacy in patients with only moderately depressed ejection fractions in situations requiring permanent right ventricular pacing. Scenarios include right ventricular pacing in atrioventricular block (Block HF, study ongoing 22 ; COMBAT [Conventional Versus Multisite Pacing for BradyArrhythmia Therapy Study] 23 and Homburg Biventricular Pacing Evaluation, 24 both completed) and atrioventricular nodal ablation in atrial fibrillation (PAVE [Left Ventricular-Based Cardiac Stimulation Post AV Nodal Ablation Evaluation], 25 APAF [Ablate and Pace in Atrial Fibrillation] 26 ). Whether LVESD may be useful in risk stratification in these populations or populations with similar systolic dysfunction but less severe symptoms (ie, MADIT-CRT [Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy], 4 RAFT [Resynchronization-Defibrillation for Ambulatory Heart Failure Trial] 5 ) is an intriguing but untested hypothesis.
Relationship Between ICD Therapy and Outcomes
Our study further demonstrates that although ICD therapy is associated with worsened clinical outcomes, the relationship is influenced by both the timing and type of electric therapy, with early therapy (<180 days postimplant) and shock therapy generally being associated with worsened outcomes. Our findings are in contrast with a previous study 12 that demonstrated that appropriate shocks (irrespective of timing) are not significantly predictive of all-cause mortality in a population with CRT. The results in our study are, however, consistent with previous analyses examining the relationship between defibrillator shocks and mortality in patients with ICDs. 27, 28 Controversy exists regarding whether arrhythmia and subsequent appropriate ICD therapy are markers of worsened overall cardiovascular status, if these arrhythmias are drivers of worsened outcomes, or both. Both scenarios are plausible, given VAs and other unfavorable cardiovascular outcomes share risk factors and VAs may precipitate HF events and ischemia, both of which have the potential to lead to death (both sudden and otherwise). Perhaps even more intriguing is the potential relationship between device therapy (namely shock therapy) and cardiovascular status. Studies have demonstrated that shock therapy can lead to decreased ejection fraction and cardiac output, 29, 30 with shocks of increasing voltage being associated with increasing degree of cardiac dysfunction. 30 Notably, an analysis by Sweeney et al 31 demonstrated that shock therapy was associated with increased mortality compared with antitachycardia pacing among patients with an ICD (without CRT) receiving device therapy for fast VT (188-250 beats per minute).
Study Limitations
This study was a retrospective analysis of a prospectively acquired cohort and thus was subject to all of the inherent limitations of such studies. It is additionally a single-center study including patients followed at a multidisciplinary CRT clinic at a tertiary care academic medical center, and thus the results may not be immediately applicable to all patients with CRT. Although the LVESD partition used in multivariate analyses was chosen a priori, it was ultimately validated in a post hoc analysis and as such requires replication in an independent data set to verify whether it is in fact the most optimal partition value. Device programming, including therapy zones, was not uniform and was left to the discretion of the treating electrophysiologist. Only appropriate device therapies for VAs were included in this analysis, and we did not investigate many other related events that might have prognostic importance, including slower VT, atrial fibrillation, nonsustained VT, and inappropriate device therapies. We did not have access to postmortem device interrogation reports for patients and were thus unable to assess the incidence of first events manifesting as device refractory VAs causing sudden cardiac death. 32 This could have led to an underestimation of the incidence of appropriate therapy in certain high-risk populations, although these patients are Comparison group used in analysis of risk associated with late events excludes patients with early (<180 d events).
*Patients with a shock at any time during follow-up were excluded. †Comparison group includes patients with ATP only or no electric therapy.
included in analyses of overall mortality. Finally, our echocardiographic measurements of left ventricular size were restricted to internal diameter measures (ie, LVESD and LVEDD), rather than volumes, which are often reported in the CRT literature.
Conclusion
Among patients with CRT-D, LVESD >61 mm is a powerful predictor of VA. Further risk stratification of patients with CRT-D with less dilated ventricles can be achieved based on assessment of ejection fraction, history of sustained VA, and absence of β-blocker therapy. The relationship between ICD therapy and adverse outcomes is impacted by both the timing and type of electric therapy, with early therapy and shocks generally predicting worsened outcomes. Comparison group used in analysis of risk associated with late events excludes patients with early (<180 d events).
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